Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. India
  4. NSE India Stock Exchange
  5. Cipla Limited
  6. News
  7. Summary
    CIPLA   INE059A01026

CIPLA LIMITED

(CIPLA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

India's Divi's Labs hits record high on Merck's positive trial data for COVID-19 drug

10/04/2021 | 02:57am EST
FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey

BENGALURU (Reuters) - Shares of India's Divi's Laboratories Ltd, which makes the main ingredient of Merck & Co's experimental antiviral pill, soared 10% on Monday, after the pharmaceutical giant reported positive clinical trial results for the drug.

Global drugmaker Merck and partner Ridgeback Biotherapeutics on Friday said molnupiravir could halve the chances of dying or being hospitalised for those most at risk of contracting severe COVID-19, according to the data released by the companies hailed as a "potential breakthrough" by experts.

The news sent Divi shares up as much as 10% to a record high, which boosted the Nifty Pharma Index 2.4% to an all time peak. Divi's in May had said it was an authorised active pharmaceutical ingredient (API) maker for molnupiravir and is allowed to supply the API to Merck's partners in India.

Shares of generic drugmakers Cipla, Sun Pharma, Dr Reddy's Laboratories and Torrent Pharmaceuticals, which are jointly conducting a clinical trial in India with molnupiravir, also gained between 1.1% and 2.3%.

In July, privately held Hetero Labs said it was also seeking a domestic emergency use nod for the experimental treatment, after interim data from its late-stage trial showed molnupiravir helped reduce hospitalisations in mild cases of COVID-19.

(Reporting by Anuron Kumar Mitra in Bengaluru; Editing by Rashmi Aich)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
CIPLA LIMITED -1.00% 912.05 Delayed Quote.12.35%
DIVI'S LABORATORIES LIMITED -0.42% 4757.05 Delayed Quote.23.82%
DR. REDDY'S LABORATORIES LIMITED -1.38% 4598 End-of-day quote.-11.65%
SUN PHARMACEUTICAL INDUSTRIES LTD. -1.89% 751.8 Delayed Quote.29.36%
TORRENT PHARMACEUTICALS LIMITED 0.40% 2984.35 End-of-day quote.6.56%
All news about CIPLA LIMITED
12/03Indian shares surrender early gains on Omicron worries
RE
12/02Indian Indices Close Higher for Second Straight Day on Thursday; Adani Ports Jumps 4%
MT
12/01Indian Indices Settle in Green Midweek; IndusInd Bank Soars 6%
MT
11/26Indian Indices End Lower on Friday; JSW Steel Plunges 8%
MT
11/26Indian shares drop most in 7 months on fears over new virus variant
RE
11/26Indian shares slide on virus variant fears, set for big weekly losses
RE
11/26Indian shares drop over 2% as new virus variant spooks investors
RE
11/26CIPLA : Disclosure of related party transactions for the half year ended 30th September 20..
PU
11/18Cipla launches Spirofy - Strengthens its lung leadership position by facilitating early..
AQ
11/17CIPLA LAUNCHES SPIROFY® : Strengthens its lung leadership position by facilitating early d..
PU
More news
Analyst Recommendations on CIPLA LIMITED
More recommendations
Financials
Sales 2022 215 B 2 859 M 2 859 M
Net income 2022 27 902 M 371 M 371 M
Net cash 2022 24 768 M 329 M 329 M
P/E ratio 2022 26,3x
Yield 2022 0,56%
Capitalization 736 B 9 778 M 9 780 M
EV / Sales 2022 3,31x
EV / Sales 2023 2,94x
Nbr of Employees 25 672
Free-Float 62,0%
Chart CIPLA LIMITED
Duration : Period :
Cipla Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CIPLA LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 35
Last Close Price 912,05 INR
Average target price 1 057,43 INR
Spread / Average Target 15,9%
EPS Revisions
Managers and Directors
Umang Vohra Global Chief Executive Officer, MD & Director
Raju Mistry President & Global Chief People Officer
Kedar Upadhye Global Chief Financial Officer
Yusuf Khwaja Hamied Non-Executive Chairman
Jaideep A. Gogtay Global Chief Medical Officer